CO2020010043A2 - Marcadores de la enfermedad de farber y usos de estos - Google Patents
Marcadores de la enfermedad de farber y usos de estosInfo
- Publication number
- CO2020010043A2 CO2020010043A2 CONC2020/0010043A CO2020010043A CO2020010043A2 CO 2020010043 A2 CO2020010043 A2 CO 2020010043A2 CO 2020010043 A CO2020010043 A CO 2020010043A CO 2020010043 A2 CO2020010043 A2 CO 2020010043A2
- Authority
- CO
- Colombia
- Prior art keywords
- farber
- markers
- disease
- diagnosis
- treatment
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01023—Ceramidase (3.5.1.23)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862648775P | 2018-03-27 | 2018-03-27 | |
| PCT/IB2019/000290 WO2019186272A1 (en) | 2018-03-27 | 2019-03-22 | Farber disease markers and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2020010043A2 true CO2020010043A2 (es) | 2020-11-10 |
Family
ID=66530353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2020/0010043A CO2020010043A2 (es) | 2018-03-27 | 2020-08-14 | Marcadores de la enfermedad de farber y usos de estos |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP3775924A1 (https=) |
| JP (2) | JP2021516757A (https=) |
| KR (2) | KR20200136367A (https=) |
| CN (2) | CN111971562A (https=) |
| AU (1) | AU2019244477A1 (https=) |
| BR (1) | BR112020016435A2 (https=) |
| CA (1) | CA3090354A1 (https=) |
| CL (1) | CL2020002105A1 (https=) |
| CO (1) | CO2020010043A2 (https=) |
| IL (2) | IL311212A (https=) |
| MX (1) | MX2020008377A (https=) |
| PH (1) | PH12020551206A1 (https=) |
| RU (1) | RU2020119065A (https=) |
| SG (1) | SG11202007508TA (https=) |
| WO (1) | WO2019186272A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020152532A1 (en) * | 2019-01-23 | 2020-07-30 | Enzyvant Therapeutics Gmbh | Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase |
| US20240180982A1 (en) * | 2021-03-29 | 2024-06-06 | University College Cardiff Consultants Limited | Modified adenovirus |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5059421A (en) | 1985-07-26 | 1991-10-22 | The Liposome Company, Inc. | Preparation of targeted liposome systems of a defined size distribution |
| US5631237A (en) | 1992-12-22 | 1997-05-20 | Dzau; Victor J. | Method for producing in vivo delivery of therapeutic agents via liposomes |
| WO1995001164A1 (en) | 1993-06-30 | 1995-01-12 | Genentech, Inc. | Method for preparing liposomes |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5643599A (en) | 1995-06-07 | 1997-07-01 | President And Fellows Of Harvard College | Intracellular delivery of macromolecules |
| CA2905449C (en) | 2013-03-14 | 2024-09-10 | Icahn School Of Medicine At Mount Sinai | THERAPEUTIC COMPOSITIONS OF ACID CERAMIDASE AND THEIR PROCESSES OF MANUFACTURE AND USE |
| EP3115786A1 (en) * | 2015-07-08 | 2017-01-11 | Centogene AG | Method for the diagnosis of farber's disease |
-
2019
- 2019-03-22 CA CA3090354A patent/CA3090354A1/en active Pending
- 2019-03-22 CN CN201980008575.9A patent/CN111971562A/zh active Pending
- 2019-03-22 JP JP2020543884A patent/JP2021516757A/ja active Pending
- 2019-03-22 RU RU2020119065A patent/RU2020119065A/ru unknown
- 2019-03-22 EP EP19723847.0A patent/EP3775924A1/en not_active Withdrawn
- 2019-03-22 KR KR1020207023065A patent/KR20200136367A/ko not_active Ceased
- 2019-03-22 IL IL311212A patent/IL311212A/en unknown
- 2019-03-22 MX MX2020008377A patent/MX2020008377A/es unknown
- 2019-03-22 CN CN202311688835.6A patent/CN118112249A/zh active Pending
- 2019-03-22 AU AU2019244477A patent/AU2019244477A1/en not_active Abandoned
- 2019-03-22 BR BR112020016435-6A patent/BR112020016435A2/pt unknown
- 2019-03-22 KR KR1020247022597A patent/KR20240111011A/ko not_active Ceased
- 2019-03-22 SG SG11202007508TA patent/SG11202007508TA/en unknown
- 2019-03-22 WO PCT/IB2019/000290 patent/WO2019186272A1/en not_active Ceased
-
2020
- 2020-07-30 IL IL276420A patent/IL276420A/en unknown
- 2020-08-07 PH PH12020551206A patent/PH12020551206A1/en unknown
- 2020-08-14 CO CONC2020/0010043A patent/CO2020010043A2/es unknown
- 2020-08-14 CL CL2020002105A patent/CL2020002105A1/es unknown
-
2023
- 2023-08-03 JP JP2023127159A patent/JP2023159164A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111971562A (zh) | 2020-11-20 |
| RU2020119065A (ru) | 2022-04-27 |
| JP2021516757A (ja) | 2021-07-08 |
| WO2019186272A1 (en) | 2019-10-03 |
| EP3775924A1 (en) | 2021-02-17 |
| AU2019244477A1 (en) | 2020-06-25 |
| CN118112249A (zh) | 2024-05-31 |
| IL276420A (en) | 2020-09-30 |
| JP2023159164A (ja) | 2023-10-31 |
| CA3090354A1 (en) | 2019-10-03 |
| MX2020008377A (es) | 2020-09-25 |
| PH12020551206A1 (en) | 2021-04-19 |
| BR112020016435A2 (pt) | 2020-12-15 |
| SG11202007508TA (en) | 2020-09-29 |
| CL2020002105A1 (es) | 2020-12-04 |
| IL311212A (en) | 2024-05-01 |
| KR20200136367A (ko) | 2020-12-07 |
| KR20240111011A (ko) | 2024-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021003191A1 (es) | Inhibidores de tead y usos de los mismos | |
| CO2021005987A2 (es) | Compuestos de anillo fusionado | |
| CL2019003627A1 (es) | Anticuerpos anti-pd-1 y sus usos. (solicitud divisional 201900628) | |
| MX2021005353A (es) | Composiciones, metodos y sistemas para el analisis de la corona proteica y usos de los mismos. | |
| CL2021003373A1 (es) | Nuevos inhibidores de egfr | |
| CL2020002161A1 (es) | Composiciones y métodos para tratar el deterioro auditivo no asociado con la edad en un sujeto humano. | |
| ECSP099619A (es) | Anticuerpos anti-robo4 y sus usos | |
| CR20200334A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| MX2017013562A (es) | Reguladores de microbioma y usos relacionados de los mismos. | |
| CL2021002503A1 (es) | Anticuerpos contra triptasa, composiciones de estos y usos de estos. (divisional de solicitud 201902251) | |
| CO2023014770A2 (es) | Degradadores de cdk2 y sus usos | |
| CO2023006684A2 (es) | Anticuerpos contra sars-cov-2 y usos de los mismos | |
| ECSP21026485A (es) | Piridazinonas y sus métodos de uso | |
| AR121390A1 (es) | Composiciones y métodos para tratar la deficiencia auditiva no relacionada con la edad en un sujeto humano | |
| CO2021014768A2 (es) | Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares | |
| ECSP20016817A (es) | Sistemas y métodos para el control de la enfermedad de necrosis hepatopancreática aguda | |
| MX2024002913A (es) | Anticuerpos anti-siglec-6 y metodos de uso de los mismos. | |
| CO2020010043A2 (es) | Marcadores de la enfermedad de farber y usos de estos | |
| MX390050B (es) | Composiciones para el cuidado personal | |
| MX2022005358A (es) | Composiciones de copolímero de bloque sensibles al ph, micelas, y métodos de uso. | |
| CO2022003324A2 (es) | Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares | |
| MX2024007050A (es) | Metodos y composiciones para mejorar la salud de los animales de compa?ia. | |
| MX2022008831A (es) | Pajuelas de inseminacion artificial serializadas y sistemas y metodos de autenticacion. | |
| ECSP22020678A (es) | Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares | |
| PL439829A1 (pl) | Zastosowanie strzyżaków jako biologicznych markerów do wykrywania chorób przenoszonych przez wektory u jeleniowatych |